Posted by Michael Wonder on 03 Dec 2021
ZetaMet receives breakthrough device designation from U.S. FDA for treatment of metastatic bone cancers
1 December 2021 - The technology is a first of its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone.
Zetagen Therapeutics today announced it has received breakthrough device designation from the Centers for Devices and Radiological Health of the U.S. FDA for its ZetaMet technology.
Previously known as ZetaFuse, ZetaMet is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumour growth and regenerating bone.
